Patent US5046499A successfully refreshed from Google Patents.
US5046499A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for myocardial infarct risk assessment
Assignee: Janssen Biotech Inc
•
Filing: 1988-06-13
•
Granted: 1991-09-10
•
Expires: 2008-06-13
Abstract
Abstract The invention pertains to a method quantitative localization of antimyosin uptake in the myocardium of a patient as an indication of myocardial infarction from a plurality of planar projections displayed simultaneously. The invention also pertains to a method for screening patients with chest pain due to myocardial ischemia to identify patients having a high risk of developing myocardial infarction.
Inventors
- 👤 Harvey J. Berger
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 08:45
CPC Classifications
A; A61; A61K; A61K49/00; A61K49/0004; A61K2123/00
Claims Analysis
Total Claims: 4
Claim 1
Independent Claim
148 words
A method for screening patients with chest pain due to myocardial ischemia to identify patients having a high risk of developing myocardial infarction comprising the steps of: a) administering an antimyosin imaging agent to the patient; b) measuring the quantity and location of antimyosin imaging agent uptake in the myocardium of the patient in a plurality of planar projections; c) displaying the planar projections simultaneously to generate a bullseye image having a preselected number of segments showing quantitatively the localization of antimyosin uptake in the myocardium of the patient; and d) correlating the antimyosin uptake with the risk of myocardial infarction wherein said step of correlating comprises classifying a patient having antimyosin uptake in less than about 30% of the bullseye image segments as a low-risk patient and a patient having antimyosin uptake in about 30% or more of the bullseye image segments as a high risk patient.
Claim 2
Independent Claim
148 words
A method for screening patients with chest pain due to myocardial ischemia to identify patients having a high risk of developing myocardial infarction comprising the steps of: a) administering an antimyosin imaging agent to the patient; b) measuring the quantity and location of antimyosin imaging agent uptake in the myocardium of the patient in a plurality of planar projections; c) displaying the planar projections simultaneously to generate a bullseye image having a preselected number of segments showing quantitatively the localization of antimyosin uptake in the myocardium of the patient; and d) correlating the antimyosin uptake with the risk of myocardial infarction wherein said step of correlating comprises classifying a patient having antimyosin uptake in less than about 30% of the bullseye image segments as a low-risk patient and a patient having antimyosin uptake in about 30% or more of the bullseye image segments as a high risk patient.
Claim 3
Dependent Claim
21 words
A method according to claim 1, wherein the antimyosin imaging agent comprises a cardiac myosin binding protein linked to a radiolabel.
Claim 4
Dependent Claim
26 words
A method according to claim 2, wherein the cardiac myosin binding protein comprises a cardiac myosin specific monoclonal antibody or fragment thereof linked to the radiolabel.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-09-09 | 1995-03-11 | 1995-09-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-09-09 | 1999-03-11 | 1999-09-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-09-09 | 2003-03-11 | 2003-09-10 | $7700.00 | Window Closed / Lapsed |